

essential role in such conditions as autoimmune diseases, graft rejection, human immunodeficiency virus infection and the generation of T cell-dependent antibodies. The Chinese herb *Tripterygium Wilfordii Hook F* (TWHF) has been used in traditional Chinese medicine for the treatment of autoimmune diseases. A major active component isolated from TWHF is triptolide and it suppresses T lymphocyte activation.

The present invention relates to compositions and methods for inhibiting the activation of dendritic cells. The methods are useful for therapies related to conditions mediated by the activation of dendritic cells with an effective amount of a composition comprising triptolide or analog or derivative thereof, thereby inhibiting activation of dendritic cells.

In addition to licensing, the technology is available for further development through collaborative research opportunities with the inventors.

#### **Wild-Type and DNA Polymerase Beta Null Mouse Embryonic Fibroblast Cell Lines Harboring a lambda-LIZ Transgene**

Robert W. Sobol, Jr., Samuel H. Wilson (NIEHS).  
DHHS Reference No. E-049-2000/0—  
Research Tool.

Licensing Contact: Marlene Shinn-Astor; (301) 435-4426;  
[shinnm@mail.nih.gov](mailto:shinnm@mail.nih.gov).

Of great utility in toxicology and DNA repair research are knockout mice with cell lines enabling one to evaluate generations of gene mutations as a direct function of base excision repair. Of particular importance are lambda-LIZ transgenes. Likewise, wild-type and beta-pol null cell lines are equally important. While there exist cell lines carrying the lambda-LIZ transgene, only wild-type cells are currently available. And while wild-type and beta-pol null cell lines exist, none carry the lambda-LIZ transgene.

The present cell line incorporates both of these beneficial properties. These cell lines were created by crossing a transgenic mouse with multiple copies of the lambda-LIZ transgene with a mouse with but a single copy of the DNA polymerase beta. Rebreeding offspring produced cells of both wild type and beta-pol null genotype. The utility of these cells stem from the deficiency in base excision repair as a result of the null mutation in the DNA polymerase beta gene.

Also available for licensing are cell lines created using: Ung KO mice + lambda-LIZ transgene; Aag KO mice +

lambda-LIZ transgene; PMS-2 KO mice + lambda-LIZ transgene; Pol-beta/Aag double KO mice + lambda-LIZ transgene; Pol-beta/PMS-2 double KO mice + lambda-LIZ transgene; Aag/PMS-2 double KO mice + lambda-LIZ transgene.

Dated: April 11, 2005.

**Steven M. Ferguson,**

*Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.*

[FR Doc. 05-7849 Filed 4-19-05; 8:45 am]

**BILLING CODE 4140-01-P**

#### **DEPARTMENT OF HEALTH AND HUMAN SERVICES**

##### **National Institutes of Health**

##### **National Cancer Institute; Notice of Closed Meeting**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Cancer Institute Special Emphasis Panel, Brain Tumors.

*Date:* June 14, 2005.

*Time:* 9 a.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Doubletree Hotel & Executive Mtg Ctr. Rockville, 1750 Rockville Pike, Rockville, MD 20852.

*Contact Person:* Claudio A. Dansky Ullmann, MD, Scientific Review Administrator, National Cancer Institute, Division of Extramural Activities, Grants Review Branch, Research Programs Review Branch, 6116 Executive Blvd., RM 8119, MSC 8328, Bethesda, MD 20892, 301-451-4761, [ullmannnc@mail.nih.gov](mailto:ullmannnc@mail.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

Dated: April 12, 2005.

**LaVerne Y. Stringfield,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 05-7861 Filed 4-19-05; 8:45 am]

**BILLING CODE 4140-01-M**

#### **DEPARTMENT OF HEALTH AND HUMAN SERVICES**

##### **National Institutes of Health**

##### **National Cancer Institute; Notice of Closed Meeting**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Cancer Institute Special Emphasis Panel, Innovations in Cancer Sample Preparations.

*Date:* June 20, 2005.

*Time:* 8 a.m. to 6 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Bethesda Marriott, 5151 Pooks Hill Road, Bethesda, MD 20814.

*Contact Person:* Kenneth L. Bielak, PhD, Scientific Review Administrator, Division Of Extramural Activities, National Cancer Institute, National Institute of Health, 6116 Executive Boulevard, Room 7147, Bethesda, MD 20892, (301) 496-7576, [bielatk@mail.nih.gov](mailto:bielatk@mail.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

Dated: April 12, 2005.

**LaVerne Y. Stringfield,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 05-7862 Filed 4-19-05; 8:45 am]

**BILLING CODE 4140-01-M**